Scientists are creating an app that examines these walking patterns to predict a child’s likelihood of having autism.

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer ...

Personal trainer explains why she believes you should lift weights to grow muscle rather than rely on low-impact methods like Pilates and yoga.

NEW YORK – Researchers led by the University of California, Los Angeles (UCLA) are calling for further investigation into reasons why guideline-recommended genetic testing for low-income children with ...

Low skeletal muscle mass, commonly observed at hospital admission, has been linked to unfavorable outcomes. Researchers conducted a retrospective study to examine the relationship between computed ...

UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) ...

Comparison of sarcopenia diagnosis defined by low muscle mass measured by bioelectrical impedance analysis (BIA) or computed tomography (CT) in combination with low muscle strength in older adults ...

Babies born with low vitamin D levels are more likely to develop mental disorders like ADHD, schizophrenia, and autism later in life.

2025-05-17 01:56 best time to check blood sugar does low blood sugar cause muscle aches And iwatch blood sugar is bitter gourd good for blood sugar. Olaf s attack speed is now faster than that of the ...

The FDA accepted the NDA for UGN-102, scheduled an ODAC meeting for May 21, 2025, and assigned a PDUFA target action date of June 13, 2025. About Low-Grade Non-Muscle Invasive Bladder Cancer (NMIBC) ...

Effect of different blood flow restriction training regimens combined with low-intensity training on muscle strength and cardiovascular safety in older adults: a systematic review and network ...

18-month DOR of 80.6% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) Data unveiled during a Podium Presentation at the American ...